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678 Original ResearchBACKGROUND: Pulmonary hypertension (PH) in COPD is a poorly investigated clinical condition.
RESEARCH QUESTION: Which factors determine the outcome of PH in COPD?
STUDY DESIGN AND METHODS: We analyzed the characteristics and outcome of patients
enrolled in the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmo-
nary Hypertension (COMPERA) with moderate or severe PH in COPD as defined during the
6th PH World Symposium who received medical therapy for PH and compared them with
patients with idiopathic pulmonary arterial hypertension (IPAH).
RESULTS: The population included incident patients with moderate PH in COPD (n ¼ 68), with
severe PH in COPD (n ¼ 307), and with IPAH (n ¼ 489). Patients with PH in COPD were older,
predominantly male, and treated mainly with phosphodiesterase-5 inhibitors. Despite similar he-
modynamic impairment, patients with PH in COPD achieved a worse 6-min walking distance
(6MWD) and showed a more advanced World Health Organization functional class (WHO FC).
Transplant-free survival rates at 1, 3, and 5 years were higher in the IPAH group than in the PH in
COPD group (IPAH: 94%, 75%, and 55% vs PH in COPD: 86%, 55%, and 38%; P ¼ .004). Risk
factors for poor outcomes in PH in COPDwere male sex, low 6MWD, and high pulmonary vascular
resistance (PVR). In patients with severe PH in COPD, improvements in 6MWD by $ 30 m or
improvements in WHO FC after initiation of medical therapy were associated with better outcomes.
INTERPRETATION: Patients with PH in COPD were functionally more impaired and had a
poorer outcome than patients with IPAH. Predictors of death in the PH in COPD group were
sex, 6MWD, and PVR. Our data raise the hypothesis that some patients with severe PH in
COPD may benefit from PH treatment. Randomized controlled studies are necessary to
explore this hypothesis further.
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Take-home Points
Research Question: Which are the clinical charac-
teristics of PH in COPD patients and what are their
impacts on outcome?
Results: Compared with patients with IPAH, pa-
tients with PH in COPD have similar hemodynamic
impairment but worse effort capacity and survival.
Risk factors for death in PH in COPD are male sex,
high age, low 6MWD, and high PVR. In patients with
severe PH in COPD (mPAP $ 35 mm Hg), im-
provements in 6MWD by $ 30 m or improvements
in WHO FC after initiation of medical therapy are
associated with better survival.
Interpretation: Patients with PH in COPD have aPulmonary hypertension (PH) is a frequent finding in
advanced COPD; its prevalence in selected populations
(candidates for lung transplantation or volume reduction
surgery) is around 50%.1-4 In these patients, PH is usually
mild to moderate, as defined by a mean pulmonary
arterial pressure (mPAP) of 21 to 34 mm Hg, but about
6% to 8% of these patients demonstrate severe PH
(mPAP $ 35 mm Hg or mPAP $ 25 mm Hg in the
presence of low cardiac output).5 The clinical importance
of PH associated with COPD has been documented in
several studies that demonstrated the independent
prognostic role of PH in this population.3,6-8
It is unclear whether patients with PH in COPD may
benefit from treating the pulmonary vascular diseasepoorer prognosis than patients with IPAH. Pre-
dictors of death in patients with PH in COPD are
related to sex, age, effort capacity, and pulmonary
vascular impairment. Some patients with severe PH
in COPD may benefit from PH treatment. Ran-
domized controlled studies are necessary to explore
this hypothesis further.
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chestjournal.orgcomponent. So far, only small randomized controlled
studies have been performed using targeted therapies
approved for pulmonary arterial hypertension (PAH)
in PH in COPD, with heterogeneous results.9-12 The
main limitations of most of these studies include lack
of power and poor selection of the populations studied
(ie, patients with COPD and normal or mildly
elevated pulmonary pressure). Although the role of
PH therapy in patients with PH in COPD remains
undefined, PAH therapies sometimes are used in these
patients.13
To obtain more information on the population with PH
in COPD, we analyzed data from the Comparative,
Prospective Registry of Newly Initiated Therapies for
Pulmonary Hypertension (COMPERA), an ongoing,
investigator-initiated, noninterventional, prospective
European-based registry that enrolls patients with all
forms of PH.14 The aim of the present study was to
describe the clinical characteristics and outcomes of a
large population of patients with PH in COPD treated
with targeted therapy (1) to compare the outcomes of
these patients with a population with idiopathic PAH
(IPAH), (2) to study the factors predicting survival in
patients with PH in COPD, (3) to compare patients with
moderate and severe PH in COPD based on the latest
recommendations from the 6th PH World Symposium,
and (4) to describe the response to PH-targeted therapy.679
Methods
Setting and Participants
COMPERA is a PH registry that was launched in July 2007 and
continues to enroll patients (www.clinicaltrials.gov Identifier:
NCT01347216). Currently, 62 PH centers from 12 countries
(Austria, Belgium, Germany, Greece, Hungary, Italy, Latvia,
Lithuania, The Netherlands, Slovakia, Switzerland, and the United
Kingdom) participate, with 84% of the patients coming from
German centers. Documentation is internet based and includes
demographics (age, sex), height and weight, type of PH according to
the Dana Point classification,15 date of the initial cardiac
catheterization, World Health Organization functional class (WHO
FC), 6-min walking distance (6MWD), hemodynamics, pulmonary
function and blood gases, selected laboratory variables, including
N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP)
and detailed information about medications for PH. The
participating centers enter all of their eligible patients on a
consecutive basis. Data are collected at the time of diagnosis
(baseline) and at least in 6-month intervals or whenever the patient
has a predefined clinical event (death, lung transplantation, PH-
related hospitalization, deterioration in functional class, any
unscheduled change in PH therapy, or other serious adverse events).
Out-of-range data or missing values are queried automatically during
data entry. As of July 2020, source data had been monitored
randomly onsite in 44 of 62 participating centers (71%). The cutoff
date for the present analysis was August 1, 2020; at that time, 10,165
patients had been enrolled into the database.
Inclusion criteria for the present analysis were a diagnosis of IPAH or
PH in COPD, age of $ 18 years, and availability of data from right
heart catheterization at diagnosis showing mPAP of > 20 mm Hg
and mean pulmonary arterial wedge pressure of # 15 mm Hg, and,
for IPAH, pulmonary vascular resistance (PVR) of > 3 Wood units.
Patients were incident cases, that is, the PH diagnosis had been
made # 6 months before inclusion. The diagnosis of IPAH or PH in
COPD was made in each center in accordance with the European
Respiratory Society and European Society of Cardiology guidelines15
and the 6th World Symposium on Pulmonary Hypertension
recommendations.16 Patients with PH in COPD were included based
on the investigator-based diagnosis and a postbronchodilator FEV1
of # 0.7 of the predicted value.
According to the 6th World Symposium on Pulmonary Hypertension
recommendations,5 the COPD population was divided in two groups
based on hemodynamics at diagnosis: (1) moderate PH in COPD,
defined as mPAP of 25 to 34 mm Hg or mPAP of 21 to 24 mm Hg
with PVR of $ 3 Wood units; (2) and severe PH in COPD, defined680 Original Researchas mPAP of > 35 mm Hg or mPAP of $ 25 mm Hg with low
cardiac index (< 2.0 L/min/m2)
The registry was approved by the institutional review boards of all
contributing centers and written informed consent was obtained
from all participating patients before start of documentation.
Guidelines on good pharmacoepidemiologic practice (GPP) and data
protection guidelines are followed. Study details may be seen at
www.COMPERA.org. COMPERA is registered at ClinicalTrials.gov
(Identifier: NCT01347216).
Definition of Therapeutic Response
To assess the impact of PH therapy, we evaluated the clinical response
from baseline to the first follow-up (after 6  3 months of therapy).
Clinical improvement was defined arbitrarily by an increase in
6MWD of $ 30 m17 or an improvement in WHO FC.
Statistical Analysis
Categorical data were displayed as number of patients and respective
relative frequency (percentage) and were compared with the c 2 test
or Fisher exact test, respectively. For continuous data, normally
distributed data were displayed as mean  SD; otherwise, median
and interquartile range were shown. Group differences for normally
distributed data were tested with a two-sided t test; otherwise, a two
sided Mann-Whitney U test was used. The primary outcome was
transplant-free survival, which was compared using Kaplan-Meier
estimates and the Breslow test. Patients with more than 5 years of
follow-up were censored after 60 months. Survival was ascertained
by patient visits to the centers or—if that was not possible—by
phone calls to the patients, their relatives, or their local physicians. A
sensitivity analysis was performed with censoring patients at the
time of treatment discontinuation. Patients lost to follow-up were
censored at the time of the last visit. To identify predictors of death
or transplantation, single-variable Cox regression analyses were
followed by multivariate Cox regression analysis. Baseline variables
preselected based on clinical reasoning and previous studies were
age, BMI, sex, 6MWD, mPAP, right atrial pressure, cardiac index,
PVR, FEV1, diffusing capacity of the lung for carbon monoxide
(DLCO), NT-proBNP (log10 transformed), and WHO FC. As a result
of left truncation, mPAP was considered only as a dichotomized
variable (< 35 mm Hg vs $ 35 mm Hg). Because of a high number
of missing and imputed values, DLCO and NT-proBNP were not
included in the multivariate model. Multiple imputation with 10
runs was applied to missing values at baseline, and results of both
the original data and pooled results of the imputed data are shown.
P values < .05 were considered significant; no adjustment was made
for multiple testing.Results
After applying the inclusion and exclusion criteria, 489
patients with IPAH, 307 patients with severe PH in
COPD, and 68 patients with moderate PH in COPD
were eligible for this analysis (Fig 1). Table 1
summarizes the clinical and hemodynamic
characteristics of the populations. Overall, patients with
PH in COPD predominantly were male and older than
patients with IPAH. Compared with patients with
IPAH, patients with PH in COPD showed more severe
airflow obstruction, lower DLCO, lower PaO2, and higher
PaCO2. Furthermore, patients with PH in COPD,particularly patients with severe PH in COPD,
demonstrated worse 6MWD and more advanced
functional class. Patients with severe PH in COPD
showed hemodynamic impairment similar to that of
patients with IPAH, whereas patients with moderate PH
in COPD showed—per definition—lower mPAP, PVR,
and preserved cardiac index.
Table 2 summarizes the use of PH drugs at baseline:
most of the patients with PH in COPD initially were
treated with oral monotherapy (mainly
phosphodiesterase-5 inhibitors [PDE-5i]) whereas in[ 1 6 0 # 2 CHES T A UGU S T 2 0 2 1 ]
10,165 patients enrolled
3,657 patients with IPAH or
COPD
2,813 incident cases
(inclusion within 6 months
of diagnosis)
2,294 incident cases with
mPAP ≥ 21 mm Hg
(and PVR ≥ 3 WU)
1,812 IPAH 482 COPD
375 COPD (FEV1 < 70%pred)
489 IPAH
(< 3 risk factors,
no atrial fibrillation,
FEV1 ≥ 70%pred.
307 COPD, severe PH
(mPAP ≥ 35 mm Hg or
mPAP ≥ 25 mm Hg and
CI < 2 L/min/m2)
68 COPD, moderate PH
(mPAP 25-34 mm Hg or
mPAP 21-24 mm Hg and
PVR ≥ 3 WU)
1,323 excluded:
487 ≥ 3 risk factors
  13 risk factors n.a.
137 atrial fibrillation
251 FEV1 < 70%pred.
435 FEV1 n.a.
107 excluded:




       criteria
199 incomplete hemodynamic
       values
  74 no right heart catheter
844 excluded:
305 patients enrolled before
       01.01.2009
539 prevalent cases
6,508 excluded:
   228 age < 18 years
2,282 non-IPAH PAH
     66 PVOD
1,066 PH-LHD
   811 non-COPD PH-Lung
1,762 CTEPH
   293 PH with multifactorial
          mechanisms
Figure 1 – Flow chart showing patient selection from the COMPERA database. CI ¼ cardiac index; CTEPH ¼ chronic thromboembolic pulmonary
hypertension; IPAH ¼ idiopathic pulmonary arterial hypertension; LHD ¼ left heart disease; mPAP ¼ mean pulmonary arterial pressure; n.a. ¼ not
assessed; PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension; PVOD ¼ pulmonary venoocclusive disease; PVR ¼ pulmonary
vascular resistance; WU ¼ Wood units.patients with IPAH, monotherapy was less common,
with a higher proportion of patients receiving
endothelin receptor antagonists.
Treatment discontinuations were more frequent in the
moderate PH in COPD group (7/64 [10.9%]) than in the
IPAH group (27/410 [6.6%]) and the severe PH in
COPD group (15/288 [5.2%]). In patients with IPAH,
63% of discontinuations were the result of lack of
tolerability and 7% were the result of efficacy failure; in
patients with severe PH in COPD, lack of tolerability
and efficacy failure accounted for 47% and 47%,
respectively, of drug discontinuations. In patients with
moderate PH in COPD, the respective numbers were
29% and 57%.chestjournal.orgTransplant-Free Survival
At least one follow-up documentation was available for
410 patients with IPAH (84%) and 352 patients (288
with severe PH and 64 with moderate PH) with PH in
COPD (94%). During follow-up, 102 deaths (24.9%) and
six lung transplantations (1.5%) occurred in the IPAH
group and 161 deaths (45.7%) and four lung
transplantations (1.1%) occurred in the PH in COPD
group. In the severe PH in COPD group, 141 deaths
(49.0%) and four lung transplantations (1.4%) occurred.
In the moderate PH in COPD group, 20 deaths (31.3%)
and no lung transplantations occurred. Estimated
transplant-free survival probabilities at 1, 3, and 5 years
in the IPAH group were 94%, 74%, and 57%, which was681
TABLE 1 ] Demographic and Baseline Characteristics of the Patients in the Study
Characteristic IPAH (n ¼ 489) COPD (n ¼ 375) P Value
PH in COPD
P ValueModerate (n ¼ 68) Severe (n ¼ 307)
Female sex 308 (63) 153 (41) < .001 34 (50) 119 (39) .102
Age, y 61.7  17.9 68.4  9.2 < .001 68.5  8.4 68.4  9.3 .96
6MWD, m 326  133 247  110 < .001 282  111 239  108 .008
BMI, kg/m2 27.1  5.9 26.2  6.1 .027 25.8  5.6 26.2  6.2 .62
WHO FC . . < .001 . . .002
I 1 (0.2) 0 . 0 0 .
II 86 (18) 10 (3) . 3 (4) 7 (2) .
III 331 (68) 260 (69) . 57 (84) 203 (66) .
IV 43 (9) 87 (23) . 5 (7) 82 (27) .
Unknown 28 (6) 18 (5) . 3 (4) 15 (5) .
Lung function tests
TLC, % predicted 98  16 107  24 < .001 108  25 106  24 .66
FVC, % predicted 93  16 67  21 < .001 69  21 67  21 .64
FEV1, % predicted 90  15 45  14 < .001 46  14 45  14 .60
DLCO, % predicted 55  22 30  15 < .001 31  15 29  15 .41
Arterial blood gases (room air values only)
PaO2, mm Hg 70  26 55  10 < .001 55  9 54  10 .65
PaCO2, mm Hg 33  6 41  9 < .001 42  8 41  9 .36
Right heart catheter
RAP, mm Hg 7.2  4.3 7.7  4.6 .13 5.3  3.6 8.3  4.6 < .001
mPAP, mm Hg 46  13 40  10 < .001 30  3 43  10 < .001
PAWP, mm Hg 8.7  3.4 9.4  3.3 .001 8.4  3.9 9.7  3.2 .018
PVR, Wood units 10.5  5.4 7.7  3.2 < .001 5.1  2.6 8.3  3.0 < .001
Cardiac index, L/min/m2 2.2  0.6 2.3  0.7 .001 2.7  0.5 2.3  0.7 < .001
SvO2, % 63  9 64  8 .036 68  6 63  9 < .001
Laboratory results
BNP, pg/mL 299 (84-578) 111 (39-311) .004 60 (26-178) 120 (44-489) .023
NT-proBNP, pg/mL 1,263 (455-3,187) 1,157 (378-2,830) .31 487 (158-1,235) 1,395 (454-3,043) < .001
Data are presented as No (%), mean  SD, or median (interquartile range), unless otherwise indicated. 6MWD ¼ 6-min walking distance; BNP ¼ brain natriuretic peptide; DLCO ¼ diffusing capacity of the lung for
carbon monoxide; IPAH ¼ idiopathic pulmonary arterial hypertension; mPAP ¼ mean pulmonary arterial pressure; NT-proBNP ¼ N-terminal fragment of pro-brain natriuretic peptide; PAWP ¼ pulmonary arterial










































ERA monotherapy 52 (11) 10 (3) < .001 1 (2) 9 (3) .70
PDE-5i monotherapy 253 (52) 346 (92) < .001 62 (91) 284 (93) .80
PCA monotherapy 0 3 (1) .081 1 (1) 2 (1) .45
Other monotherapya 45 (9) 3 (1) < .001 0 3 (1) 1.00
ERA þ PDE-5i 92 (18) 4 (1) < .001 0 4 (1) 1.00
Other double-combination
therapies
29 (6) 8 (2) .006 3 (4) 5 (2) .16
Triple-combination therapy 18 (4) 1 (0.3) .001 1 (2) 0 .18
Data are presented as No. (%), unless otherwise indicated. ERA ¼ endothelin-receptor antagonist; IPAH ¼ idiopathic pulmonary arterial hypertension;
PCA ¼ prostacyclin analog; PDE-5i ¼ phosphodiesterase-5 inhibitor; PH ¼ pulmonary hypertension.
aIncludes soluble guanylate cyclase stimulators (IPAH 2.7%, COPD 0.5%) and calcium channel blockers (IPAH 6.5%, COPD 0.3%).significantly better than the respective transplant-free
survival rates in the PH in COPD group (86%, 55%, and
38%; P < .001). The difference in transplant-free
survival remained statistically significant when adjusted
for age and sex (P ¼ .004). When censoring patients
who discontinued PH therapy, the results remained
similar: survival rates at 1, 3, and 5 years were 95%, 75%,
and 57% in the IPAH group and 86%, 56%, and 39% in
the PH in COPD group, respectively (P < .001) (e-Fig
1). Comparing the transplant-free survival rates between
the two PH in COPD groups, patients with severe PH in
COPD experiences worse outcomes than patients with
moderate PH in COPD, with estimated survival
probabilities at 1, 3, and 5 years of 84%, 52%, and
36% compared with 95%, 68%, and 49%, respectively
(P ¼ .009) (Fig 2). These differences remained
statistically significant when patients were censored at
the time of treatment discontinuation: survival rates
were 94%, 68%, and 47% in the moderate PH in COPD
group and 84%, 53%, and 38% in the severe PH in
COPD group, respectively (P ¼ .018) (e-Fig 1).
In the univariate Cox regression analysis, baseline
variables associated with transplantation or death in
those with PH in COPD were higher age, low 6MWD,
high mPAP, high PVR, and high NTpro-BNP (Table 3).
In the multivariate approach, male sex, low 6MWD, and
high PVR remained associated independently with
transplant-free survival; however, sex and PVR were
statistically significant only in the imputed multivariate
model, not in the original multivariate model, the latter
based on much smaller numbers of patients (Table 4).
Response to Therapy and Survival
At follow-up, 6MWD was available in for 209 patients
with IPAH (42.7%) and 160 patients with PH in COPDchestjournal.org(42.7%). WHO FC assessment was collected for 285
patients with IPAH (58.3%) and for 246 patients with
PH in COPD (65.6%). The frequency of 6MWD
improvement of$ 30 m from baseline was similar in the
PH in COPD group compared with the IPAH group
(46.9% vs 52.6%; P ¼ .294), with considerable
differences between the severe PH in COPD group and
the moderate PH in COPD group (51.6% vs 31.6%; P ¼
.04). WHO FC improved by $ 1 class in 35.8% of
patients with IPAH and in 28.5% of patients with PH in
COPD (P ¼ .078), with no difference based on
traditional statistical thresholds in severe PH in COPD
compared with moderate PH in COPD (30.4% vs 19.0%;
P ¼ .188).
Associated with a response to therapy in the PH in
COPD group were a low 6MWD and a high WHO FC at
baseline, whereas pulmonary function and
hemodynamics did not differ between responders and
nonresponders. In the IPAH group, younger age, higher
DLCO, higher mPAP, lower PCO2, and higher WHO FC
were associated with response to therapy (e-Table 1).
Stratifying the patients with PH in COPD based on
clinical response at 6 months, we found that patients
who met the criteria of a clinical improvement
experienced a better transplant-free survival than
patients who did not meet this criterion (Fig 3A). This
observation was restricted to patients with severe PH in
COPD (Fig 3B, 3C).
Discussion
The present study describes the characteristics and
outcome of patients with PH in COPD treated with
medications approved for PAH. Our results show that


























307 232 156 117 68
352 266 190 128 88 68
64
No. at risk:
48 39 23 19 14
288 218 151 105 69 54
IPAH COPD COPD moderate PH severe PH
Figure 2 – A, B, Kaplan-Meier plots showing 5-year survival free from lung transplantation of patients with IPAH and PH in COPD (A) and severe and
moderate PH in COPD (B). IPAH ¼ idiopathic pulmonary arterial hypertension; PH ¼ pulmonary hypertension.status and a lower transplant-free survival than patients
with IPAH, despite similar hemodynamic impairment.
The risk of transplantation or death in patients with PH
in COPD was not related to the degree of airflow
obstruction, but rather to male sex, low 6MWD, and
high PVR. Patients with severe PH in COPD achieved
worse outcomes than patients with moderate PH in
COPD, providing evidence that the distinction between
moderate and severe PH in COPD, as proposed during
the latest PH world symposium, has clinical relevance.5
In addition, our data raise the possibility that some
patients with severe PH in COPD may benefit from
treatment with PAH medications.
The COPD population in the present series consisted
mainly of patients with severe PH. The hemodynamic
profile of these patients was similar to that of patients
with IPAH. These findings suggest the presence of a
severe pulmonary arteriopathy.18
Despite similar hemodynamic impairment, patients with
severe PH in COPD showed a worse effort tolerance and
worse prognosis than patients with IPAH, even when
adjusted for age and sex. The mortality rate was around
12% per year in patients with severe PH in COPD, that684 Original Researchis, about twice the observed mortality rate in the IPAH
population. These findings are in line with previous
observations.13,19,20 It remains unclear whether the
survival differences between these entities result from
differences in the underlying diseases, comorbidities, or
different treatment patterns.
These observations underscore the need for better
treatment options in patients with PH in COPD. Drugs
approved for the treatment of PAH have been explored
in patients with PH in COPD, but with inconsistent and
mostly negative results. Bosentan, an endothelin
receptor antagonist, not only failed to improve exercise
capacity, but also caused a deterioration in gas exchange
and functional status in patients with advanced COPD
and mild PH.9 In a similar population, tadalafil, a PDE-
5i, showed no effect on effort capacity and quality of
life.11 In a dose comparison study evaluating the acute
hemodynamic effects of sildenafil, another PDE-5i,
Blanco and colleagues21 showed a significant reduction
in mPAP at rest and during exercise with an impairment
of gas exchange at rest, but not during exercise. In two
other studies in patients with COPD with borderline or
mild PH, sildenafil failed to demonstrate an
improvement in effort capacity.10,22,23[ 1 6 0 # 2 CHES T A UGU S T 2 0 2 1 ]
TABLE 3 ] Univariate Cox Regression Model of Predictors for Death or Lung Transplantation in the PH in COPD
Cohort for the Original Data and the Multiple Imputed Dataset
Variable
Original Data Pooled Imputed Dataset (n ¼ 351a)
Imputed ValuesRisk Ratio (95% CI) P Value Risk Ratio (95% CI) P Value
6MWD, per 10 m 0.97 (0.96-0.99) < .001 0.97 (0.96-0.98) < .001 22.4
Age at inclusion, per 5 y 1.11 (1.02-1.21) .011 1.11 (1.02-1.21) .011 0.0
BMI, per 1 kg/m2 0.97 (0.94-0.995) .022 0.98 (0.96-1.01) .165 8.5
Cardiac index, per 0.5 L/min/m2 0.89 (0.80-0.99) .040 0.91 (0.82-1.01) .075 7.4
DLCO, per 10% predicted 0.88 (0.77-1.01) .073 0.88 (0.78-1.00) .055 38.9
FEV1, per 10% predicted 0.98 (0.88-1.10) .772 0.98 (0.88-1.10) .772 0.0
NT-proBNP, log10 transformed 1.50 (1.09-2.06) .012 1.37 (1.02-1.82) .035 43.2
WHO FC (reference, II) .207 4.5
III 1.84 (0.59-5.78) .296 1.94 (0.61-6.21) .262 4.5
IV 2.27 (0.71-7.24) .166 2.46 (0.76-7.96) .135 4.5
PVR, per 1 Wood unit 1.07 (1.03-1.11) .001 1.07 (1.03-1.11) .001 4.5
RAP, per 3 mm Hg 1.07 (0.98-1.17) .108 1.07 (0.98-1.17) .120 5.4
mPAP $ 35 mm Hg 1.39 (1.02-1.90) .038 1.39 (1.02-1.90) .038 0
Male sex 1.19 (0.89-1.58) .236 1.19 (0.89-1.58) .236 0
Data are presented as percentage, unless otherwise indicated. 6MWD ¼ 6-min walking distance; DLCO ¼ diffusing capacity of the lung for carbon monoxide;
mPAP ¼ mean pulmonary arterial pressure; NT-proBNP ¼ N-terminal fragment of pro-brain natriuretic peptide; PVR ¼ pulmonary vascular resistance;
RAP ¼ right atrial pressure; WHO FC ¼ World Health Organization functional class.
aOne patient was censored before the first event (death).A main drawback of these studies is that most of the
enrolled patients had mild or moderate PH. Thus, it may
not be surprising that PH-targeted therapy did not result in
improvement in hemodynamics or exercise capacity. In
fact, in a study that included only patients with severe PH in
COPD, sildenafil demonstrated significant improvementsTABLE 4 ] Multivariate Cox PH Regression Model of Predicto
Cohort for the Original Data and the Multiple Im
Variable
Original Data
Risk Ratio (95% CI)
6MWD, per 10 m 0.96 (0.94-0.98)
Age at inclusion, per 5 y 1.07 (0.96-1.19)
BMI, per 1 kg/m2 0.96 (0.92-0.99)
Cardiac index, per 0.5 L/min/m2 0.93 (0.79-1.10)
FEV1, per 10% predicted 1.02 (0.88-1.19)
WHO FC (reference, II)
III 0.61 (0.13-2.82)
IV 0.44 (0.08-2.28)
PVR, per 1 Wood unit 1.05 (0.97-1.14)
RAP, per 3 mm Hg 0.99 (0.87-1.12)
mPAP $ 35 mm Hg 1.17 (0.72-1.89)
Male sex 1.40 (0.95-2.05)
6MWD ¼ 6-min walking distance; mPAP ¼ mean pulmonary arterial pressur
RAP ¼ right atrial pressure; WHO FC ¼ World Health Organization functional c
aFor number of imputed values, see Table 3.
chestjournal.orgin hemodynamics and BMI, airflow obstruction, dyspnea,
and exercise capacity in COPD index without significant
deterioration in PaO2 compared with placebo.
12
In the present series, most of the patients in the PH in
COPD cohort were treated with PDE5-i. After 6 months,rs for Death or Lung Transplantation in the PH in COPD
puted Data Set
(n ¼ 211) Pooled Imputed (n ¼ 351a)
P Value Risk Ratio (95% CI) P Value
.001 0.97 (0.95-0.98) < .001
.244 1.08 (0.98-1.18) .106
.019 0.97 (0.94-1.00) .060
.388 1.03 (0.91-1.17) .630
.754 0.97 (0.86-1.10) .669
.529 1.40 (0.40-4.91) .594
.327 1.33 (0.37-4.81) .666
.198 1.06 (1.00-1.12) .042
.852 1.06 (0.96-1.17) .275
.530 1.18 (0.82-1.70) .366
.092 1.54 (1.12-2.11) .008
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Figure 3 – A-C, Kaplan-Meier plots showing 5-year survival free from lung transplantation of patients with PH in COPD with and without treatment
response defined as improvement in WHO FC or 6MWD $ 30 m at 6 months: total (A), patients with severe PH (B), and patients with moderate PH
(C). 6MWD ¼ 6-min walking distance; PH ¼ pulmonary hypertension; WHO FC ¼ World Health Organization functional class.46.9% of the patients showed improvement in 6MWD
of$ 30 m, and 28.5% showed an improvement in WHO
FC (16.2% showed improvements in both criteria).686 Original ResearchThese numbers compared well with the present IPAH
cohort and are consistent with the abovementioned data
from Vitulo and colleagues.12[ 1 6 0 # 2 CHES T A UGU S T 2 0 2 1 ]
Another potentially relevant finding of the present study
is the observed association of a clinical response to PH
therapy and transplant-free survival in patients with
severe PH in COPD. Our results suggest that patients
with severe PH in COPD with a clinical response to PH-
targeted therapy (herein identified arbitrarily as an
improvement in 6MWD of $ 30 m or improvement in
WHO FC) achieved a better transplant-free survival
compared with patients who did not meet this responder
criterion. Of note, this observation was restricted to the
subgroup of patients with severe PH in COPD. In
addition, patients with moderate PH in COPD showed a
higher rate of PH drug discontinuations compared with
patients with severe PH in COPD or IPAH. These
aspects may be of potential relevance when designing
future trials in this patient population.
Our findings are in line with previous observations by
Hurdman and colleagues19 in a series of 43 patients with
severe PH in COPD. In that study, a decline in PVR of
> 20% or improvement in WHO FC after initiation of
PH drugs identified patients with a better survival
compared with patients who did not respond. Taken
together, these observational experiences suggest that
some patients with severe PH in COPD may benefit
from drug therapy targeting PH and support the need
for randomized controlled trials in this area.
Study Limitations
The main limitations of the present study are related to
the intrinsic nature of a registry and include lack ofchestjournal.orgstandardized assessment of the lung disease, missing
values for some variables, and lack of systematic
assessment of hemodynamics and blood gases during
follow-up. Only a limited number of PFT data were
captured in the electronic database, and data on imaging
were not available, so we cannot exclude the possibility
that some patients were misclassified. In addition, none
of the patients with PH in COPD received no medical
therapy targeting PH. Hence, the study had no control
group and selection bias cannot be excluded. In terms of
efficacy of medical interventions, registry data have to be
viewed as hypothesis generating. As such, our data do
not provide evidence that PH drugs are beneficial in
patients with PH in COPD, and they are not intended to
encourage physicians to use these drugs outside the
setting of clinical trials.
Interpretation
In the present series, patients with PH in COPD had a
poorer prognosis than patients with IPAH. The risk of
death in patients with PH in COPD was predicted by
male sex, a low 6MWD, and high PVR. Our data suggest
that PH-targeted drug therapy in patients with COPD
and severe PH may improve exercise tolerance and
WHO FC in a subgroup of patients and that patients
with COPD and PH who respond to therapy may have a
better prognosis than patients who do not show clinical
improvement. These findings need to be explored
further in prospective, randomized controlled clinical
studies.687
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